Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Return on Equity (2016 - 2023)

Endonovo Therapeutics has reported Return on Equity over the past 10 years, most recently at 0.19% for Q3 2023.

  • Quarterly results put Return on Equity at 0.19% for Q3 2023, up 3.0% from a year ago — trailing twelve months through Sep 2023 was 0.19% (up 3.0% YoY), and the annual figure for FY2022 was 0.77%, up 56.0%.
  • Return on Equity for Q3 2023 was 0.19% at Endonovo Therapeutics, up from 0.18% in the prior quarter.
  • Over the last five years, Return on Equity for ENDV hit a ceiling of 1.06% in Q2 2019 and a floor of 0.03% in Q4 2020.
  • Median Return on Equity over the past 5 years was 0.37% (2020), compared with a mean of 0.43%.
  • Biggest five-year swings in Return on Equity: tumbled -91bps in 2020 and later soared 53bps in 2022.
  • Endonovo Therapeutics' Return on Equity stood at 0.93% in 2019, then crashed by -97bps to 0.03% in 2020, then soared by 527bps to 0.18% in 2021, then surged by 291bps to 0.71% in 2022, then plummeted by -73bps to 0.19% in 2023.
  • The last three reported values for Return on Equity were 0.19% (Q3 2023), 0.18% (Q2 2023), and 0.31% (Q1 2023) per Business Quant data.